Biopharmas raising money in public or private financings, including: Altamira, Faron, Fzata, Ivexsol and Oxurion.

HBM Alpha Therapeutics Inc. has completed seed financing to advance its lead programs, novel antibody therapies to treat congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).

An anticancer approach that leads to improved tumor visibility edged closer to the clinic after Grey Wolf Therapeutics Ltd. scooped $49 million in a series B round. The Oxford, U.K.-based immuno-oncology company plans to use the proceeds to move its lead candidate, GRWD-5769, into a phase I/II trial.

Med-tech firms raising money in public or private financings, including: Alleviant Medical.

Biopharmas raising money in public or private financings, including: Genelux, Harbour, HBN, Hemogenyx, Iaso, Inhibikase, Panbela, Tetra.

Coming off a tough year for raising money, Cadrenal Therapeutics Inc. is leading the charge into a new year by completing 2023’s first U.S. IPO. The company closed its IPO of 1.4 million shares at $5 each for $7 million. The stock (NASDAQ:CVKD) began trading Jan. 20 and closed 9.37% downward on Jan. 25 at $2.90 per share.

Med-tech firms raising money in public or private financings, including: Miach Orthopaedics.

Biopharmas raising money in public or private financings, including: Atomic, Deciphera, Jasper, Myosana, Oxurion, Precigen, Pliant, Rewind, Verastem.

Med-tech firms raising money in public or private financings, including: Endosound, Julier Medical.